← Neumora Therapeutics, Inc. (NMRA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Neumora Therapeutics, Inc. (NMRA)
Biological Products, (No Diagnostic Substances) · market cap $133M · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Neumora Therapeutics (NMRA) is a clinical-stage CNS biotech with a $306M market cap and ~95 employees, built around NMRA-335140, a Phase 3 asset targeting Major Depressive Disorder. The company carries roughly 9.5 months of cash runway on $147.1M in cash, with no disclosed revenue and annual R&D burn in the $143–201M range over the past three years.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| NMRA-335140 | Phase 3 | Major Depressive Disorder |
| NMRA-335140 80 mg | Phase 2 | Major Depressive Episode Associated With Bipolar II Disorder |
Price & technical context
3-month
-67.1%
6-month
-73.7%
12-month
-69.8%
52-wk range
$0.55–$3.59
vs 50-day MA
-57.5%
vs 200-day MA
-71.6%
Realized vol
124.0%
Max drawdown
-96.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NMRA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.